Sep 12 |
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
|
Sep 9 |
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
|
Sep 4 |
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
|
Aug 27 |
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
|
Aug 9 |
ALX Oncology GAAP EPS of -$0.76 in-line
|
Aug 8 |
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
Aug 6 |
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
|
Aug 1 |
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
|
Aug 1 |
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
|
Aug 1 |
ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial
|